文献速递前列腺癌

铁死亡在去势抵抗性前列腺癌治疗中的进展:新型药物靶点与联合治疗策略

Advances in ferroptosis for castration-resistant prostate cancer treatment: novel drug targets and combination therapy strategies.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-12-28

本文综述铁死亡的机制与特征及其在去势抵抗性前列腺癌(CRPC)中的作用,梳理PI3K/AKT/mTOR、DECR1等铁死亡调控因子及erastin、BSO、RSL3、FIN56等诱导剂的研究证据,并总结铁死亡与放疗联合的策略及基于铁死亡相关基因的预后风险模型。

要点

  • PI3K/AKT/mTOR、DECR1等铁死亡调控因子在CRPC发生发展中起重要作用。
  • erastin、BSO、RSL3、FIN56等铁死亡诱导剂已在CRPC相关研究中显示作用。
  • GPX4和SLC7A11抑制剂可提高放射敏感性,为联合治疗提供新策略。

核心结论

  • 铁死亡可作为CRPC的潜在治疗靶点,并可能成为联合治疗的新策略。
  • 铁死亡相关基因可能是前列腺癌预后的良好指标。
  • 本综述提供的框架可为进一步研究铁死亡在CRPC治疗中的应用提供参考。

研究设计与样本

  • 本文为综述,围绕铁死亡机制与特征、铁死亡对CRPC的作用、铁死亡与CRPC治疗的关系以及铁死亡预测CRPC预后四个方面进行回顾。

主要发现

  • PI3K/AKT/mTOR、DECR1等铁死亡调控因子在CRPC发展中具有重要作用。
  • erastin、BSO、RSL3和FIN56等铁死亡诱导剂已在CRPC相关研究中显示出作用。
  • 铁死亡通过诱导脂质过氧化及调控p53、AMPK等参与辐射诱导的抗癌效应。
  • 某些GPX4和SLC7A11抑制剂可提高放射敏感性。
  • 已开发出若干基于铁死亡相关基因的风险模型并显示出有前景的预测能力。

关键数值与推荐

  • 铁死亡由铁依赖性脂质过氧化触发,引起程序性细胞死亡,并与CRPC相关。
  • PI3K/AKT/mTOR、DECR1等为铁死亡调控因子;erastin、BSO、RSL3、FIN56为铁死亡诱导剂;GPX4、SLC7A11为可提高放射敏感性的抑制靶点。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metastatic prostate cancer (PCa) has much lower survival and ultimately develops castration resistance, which expects novel targets and therapeutic approaches. As a result of iron-dependent lipid peroxidation, ferroptosis triggers programmed cell death and has been associated with castration-resistant prostate cancer (CRPC). SUBJECTS: To better understand how ferroptosis can be used to treat CRPC, we reviewed the following: First, ferroptosis mechanisms and characteristics. We then pay attention to ferroptosis effects on CRPC, and the relationship between ferroptosis and CRPC treatment. Finally, we'd like to figure out if ferroptosis could predict the prognosis of CRPC thus screening early for populations that may benefit from appropriate therapies. RESULTS: The review demonstrated that ferroptosis regulators like PI3K/AKT/mTOR, DECR1 et al., have a significant role in the development of CRPC and that several inducers of ferroptosis, such as erastin, BSO, RSL3, and FIN56, have already demonstrated their effects in that area. What's more, ferroptosis is crucial for radiation-induced anticancer effects by inducing lipid peroxidation and regulating p53, AMPK, and others. Additionally, it has been discovered that certain GPX4 and SLC7A11 inhibitors can increase radiosensitivity, which brings new combination strategies. Finally, among the genes associated with ferroptosis, which may be excellent predictors of prostate cancer prognosis, several risk models have been developed and shown promising predictive capabilities. CONCLUSIONS: Ferroptosis can serve as a potential therapeutic target for CRPC, and could be a new strategy for combination therapy. Moreover, ferroptosis-related genes may be great indicators of PCa prognosis. Further research on ferroptosis in CRPC therapy can benefit from the frameworks provided by this review.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Chen H, Lyu F, Gao X, et al. Advances in ferroptosis for castration-resistant prostate cancer treatment: novel drug targets and combination therapy strategies. Prostate Cancer Prostatic Dis. 2024. PMID: 39733054. doi:10.1038/s41391-024-00933-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。